@article{fdi:010085283,
  title = {{C}ellular and antibody response in {GMZ}2-vaccinated {G}abonese volunteers in a controlled human malaria infection trial},
  author = {{N}ouatin, {O}. and {I}banez, {J}. and {F}endel, {R}. and {N}goa, {U}. {A}. and {L}orenz, {F}. {R}. and {D}ejon-{A}gobe, {J}. {C}. and {E}doa, {J}. {R}. and {F}lugge, {J}. and {B}ruckner, {S}. and {E}sen, {M}. and {T}heisen, {M}. and {H}offman, {S}. {L}. and {M}outairou, {K}. and {L}uty, {A}drian and {L}ell, {B}. and {K}remsner, {P}. {G}. and {A}degnika, {A}. {A}. and {M}ordmuller, {B}.},
  editor = {},
  language = {{ENG}},
  abstract = {{B}ackground: {A}ntibody and cellular memory responses following vaccination are important measures of immunogenicity. {T}hese immune markers were quantified in the framework of a vaccine trial investigating the malaria vaccine candidate {GMZ}2. {M}ethods: {F}ifty {G}abonese adults were vaccinated with two formulations (aluminum {A}lhydrogel and {CAF}01) of {GMZ}2 or a control vaccine ({V}erorab). {V}accine efficacy was assessed using controlled human malaria infection ({CHMI}) by direct venous inoculation of 3200 live {P}lasmodium falciparum sporozoites ({P}f{SPZ} {C}hallenge). {GMZ}2-stimulated {T} and specific {B}-cell responses were estimated by flow cytometry before and after vaccination. {A}dditionally, the antibody response against 212 {P}. falciparum antigens was estimated before {CHMI} by protein microarray. {R}esults: {F}requencies of pro- and anti-inflammatory {CD}4(+){T} cells stimulated with the vaccine antigen {GMZ}2 as well as {B} cell profiles did not change after vaccination. {IL}-10-producing {CD}4(+) {T} cells and {CD}20(+) {I}g{G}(+) {B} cells were increased post-vaccination regardless of the intervention, thus could not be specifically attributed to any malaria vaccine regimen. {I}n contrast, {GMZ}2-specific antibody response increased after the vaccination, but was not correlated to protection. {A}ntibody responses to several {P}. falciparum blood and liver stage antigens ({MSP}1, {MSP}4, {MSP}8, {P}f{EMP}1, {STARP}) as well as the breadth of the malaria-specific antibody response were significantly higher in protected study participants. {C}onclusions: {I}n lifelong malaria exposed adults, the main marker of protection against {CHMI} is a broad antibody pattern recognizing multiple stages of the plasmodial life cycle. {D}espite vaccination with {GMZ}2 using a novel formulation, expansion of the {GMZ}2-stimulated {T} cells or the {GMZ}2-specific {B} cell response was limited, and the vaccine response could not be identified as a marker of protection against malaria.},
  keywords = {{GMZ}2 ; {C}ytokine ; {M}emory {B} cells ; {P}. falciparum ; {CHMI} ; {M}icroarray ; {GABON}},
  booktitle = {},
  journal = {{M}alaria {J}ournal},
  volume = {21},
  numero = {1},
  pages = {191 [16 p.]},
  year = {2022},
  DOI = {10.1186/s12936-022-04169-8},
  URL = {https://www.documentation.ird.fr/hor/fdi:010085283},
}